Merck/Shering
Executive Summary
Former researcher Bernard Mayles, PhD, and Biopharm Research head Mario Miscio, PhD, will be sentenced on May 20, following their convictions last week for selling trade secrets involving Merck's ivermectin (Mectizan) and Schering's interferon (Intron-A). Found guilty by a jury of 12 counts of conspiracy and wire fraud, each could face up to 65 years in jail and hundreds of millions of dollars in fines. The two were initially charged on Aug. 21 after they tried to sell the trade secrets to an under cover FBI agent for approximately $10 mil. ("The Pink Sheet" Aug. 27, T&G-12). The FBI was alerted to the scam by the security department of one of the pharmaceutical firms.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth